E-Book Overview
This resource provides thorough coverage of pharmacogenetics and its impact on pharmaceuticals, therapeutics, and clinical practice. It opens with the basics of pharmacogenetics, including drug disposition and pharmacodynamics. The following section moves into specific disease areas, including cardiovascular, psychiatry, cancer, asthma/COPD, adverse drug reactions, transplantation, inflammatory bowel disease, and pain medication. Clinical practice and ethical issues make up the third section, with the fourth devoted to technologies like genotyping, genomics, and proteomics. In the fifth part, chapters discuss the impact of key regulatory issues on the pharmaceutical industry.Content: Chapter 1 Pharmacogenetics: A Historical Perspective (pages 1–12): Ann K. DalyChapter 2 Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes (pages 13–80): Vita DolzanChapter 3 Pharmacogenetics of Phase II Drug Metabolizing Enzymes (pages 81–100): Ingolf CascorbiChapter 4 Pharmacogenetics of Drug Transporters (pages 101–148): Henriette E. Meyer zu Schwabedissen, Markus Grube and Heyo K. KroemerChapter 5 Pharmacogenetics of Drug Targets (pages 149–182): Ann K. Daly and Maria ArranzChapter 6 Cardiovascular Pharmacogenetics (pages 183–213): Bas J. M. Peters, Anthonius de Boer, Tom Schalekamp, Olaf H. Klungel and Anke?Hilse Maitland?van der ZeeChapter 7 Pharmacogenetics in Psychiatry (pages 215–250): Evangelia M. Tsapakis, Sarah Curran, Ruth I. Ohlsen, Nora S. Vyas, Katherine J. Aitchison and Ann K. DalyChapter 8 Pharmacogenetics in Cancer (pages 251–270): Sharon MarshChapter 9 Pharmacogenetics of Asthma and COPD (pages 271–294): Ellen S. Koster, Jan A. M. Raaijmakers, Anke?Hilse Maitland?van der Zee and Gerard H. KoppelmanChapter 10 Pharmacogenetics of Adverse Drug Reactions (pages 295–321): Ann K. Daly, Martin Armstrong and Munir PirmohamedChapter 11 Pharmacogenomics of Inflammatory Bowel Diseases (pages 323–351): Alexander Teml, Susanne Karner, Elke Schaeffeler and Matthias SchwabChapter 12 Pharmacogenetics of Pain Medication (pages 353–374): Jorn LotschChapter 13 Ethical and Social Issues in Pharmacogenomics Testing (pages 375–400): Susanne Vijverberg, Toine Pieters and Martina CornelChapter 14 High?Throughput Genotyping Technologies for Pharmacogenetics (pages 401–414): Beatriz Sobrino and Angel CarracedoChapter 15 Developments in Analyses in Pharmacogenetic Datasets (pages 415–435): Alison A. Motsinger?ReifChapter 16 Applications of Pharmacogenetics in Pharmaceutical Research and Development (pages 437–460): Daniel K. Burns and Scott S. SundsethChapter 17 Role of Pharmacogenetics in Registration Processes (pages 461–475): Myong?Jin Kim, Issam Zineh, Shiew?Mei Huang and Lawrence J. LeskoChapter 18 Pharmacogenetics: Possibilities and Pitfalls (pages 477–483): Anke?hilse Maitland?van der Zee and Ann K. Daly
E-Book Content
PHARMACOGENETICS AND INDIVIDUALIZED THERAPY PHARMACOGENETICS AND INDIVIDUALIZED THERAPY Edited by Anke-Hilse Maitland-van der Zee Utrecht University Utrecht, The Netherlands Ann K. Daly Newcastle University, Newcastle upon Tyne, UK Copyright Ó 2012 by John Wiley & Sons, Inc. All rights reserved. Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-750-4470, or on the web at www.copy